DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contributio

Wednesday, 27 April 2016

Veronica (Novotny) Diermayr

 Veronica (Novotny) Diermayr; PhD

Veronica (Novotny) Diermayr; PhD

Head of Development at D3 (Drug Discovery and Development), BMSI



* Broad understanding of cancer biology, holistically applied to the discovery and development of drugs and biomarkers.
Experienced in preclinical and early clinical development in oncology & infectious diseases and immunology for small molecule and biologics

* Proven ability to contribute to preclinical and Phase 1/2 development, biomarker development and validation, medical rationale & positioning, study protocol development and Investigator's Brochure writing

* Excellent scientific, leadership, personal management and organizational skills

* Knowledgeable and trained in GLP and GCP and a very keen interest in the medical aspects of oncology and immunology

* Keen, enthusiasticand emphathetic team worker with a “can-do” attitude, good mentoring skills and proven leadership qualities

Specialties: Key areas of expertise: biomarker development, pre-clinical and early clinical development (Phase 0 – 2) in the areas of oncology, immunology, infectious diseases; in-depth and hands-on knowledge of animal efficacy studies, pharmacodynamics and PK/PD models, in vitro kinase assays, molecular biology, signal transduction, protein production, clinical research, project management, scientific writing


Head of Development

D3 (Drug Discovery and Development), BMSI
– Present (1 year 1 month)Singapore

Head of Project Management

D3 (Drug Discovery and Development), BMSI
– Present (4 years 3 months)Singapore
As a Project Manager and biomarker expert in D3 we are currently doing the pre-clinical development of an anti-neoplastic small molecule (wnt signaling inhibitor) for solid tumors targeting to obtain an IND by Sept. 2014.
We have successfully completed the a Phase I, first-in man, healthy volunteer, multi-center study testing a VLP-vaccine.

Our small- molecule kinase inhibitors for the treatment of a subset of chronic myeloid leukemia patients are just entering preclinical development. Furthermore D3 is in the process of in-licensing two exciting first-in class oncology compounds.
In the non-oncology area we are involved in the preclinical development of MSC exosomes for small indications for PoC.

Team Leader

S*BIO Pte Ltd
(6 years)Singapore
- Project management & leadership for biomarker group and animal pharmacology group
- Biology leader for an early stage drug discovery project
- Coordinate research with other teams
- Manage CROs for various outsourced studies
- Coordinate work with clinical study teams to validate and apply biomarkers for clinical trials
- Operationally support the application of validated biomarkers for clinical trials
- Organize, report and communicate study outcome to the project team
- Write & submit scientific publications as corresponding author
- Deliver & present data packages & scientific rationale for filings (IND, FDA, reports etc)
- present to senior management/international community
- perform as an effective leader who supervises and coaches research associates

Senior Reserach Fellow

Institute for Molecular and Cell Biology (IMCB), Singapore
(5 years 3 months)Singapore
Molecular Biology studies in the field of Oncology

Research Fellow

Novartis Research Institute, Vienna, Austria
(3 years 1 month)Vienna
Mast Cells & Dendritic cells, Sphingosine Kinase pathways, compound screening for novel inhibitors
(Open)1 organization

Research fellow, Vienna Medical University, Institute of Immunology

VIRC - Vienna International Reserach Cooperation, Institute of Immunology (Prof. Knapp)
(1 year)
studied the active signal transduction pathways in patients with Wiskott-Aldrich Syndrome using EBV transformed B-cells


Haematological Society Austria



Full Member


Phase 1 and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939,in patients with refractory solid malignancies

Annals of Oncology
March 8, 2011

Phase I Clinical, Pharmacokinetic and Pharmacodynamic Study of SB939, an Oral Histone Deacetylase Inhibitor (HDACi), in Patients with Advanced Solid Tumors

British Journal of Cancer
February 1, 2011

SB939, a novel potent and orally active histone deacetylase inhibitor with high exposure and efficacy in mouse models of colorectal cancer

Molecular Cancer Therapeutics
March 2, 2010

VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer(Link)

Molecular Cancer Therapeutics
December 27, 2012
2 authors
  • Veronica Diermayr; PhD
    Veronica Diermayr; PhD
    Head of Development at D3 (Drug Discovery and Development), BMSI
  • Stefan Hart
    Stefan Hart
    Director, New Ventures Singapore/SEA/India at Johnson & Johnson Innovation Center Asia Pacific

Modulation of the interleukin-6 receptor subunit glycoprotein 130 complex and its signaling by LMO4 interaction

Journal of Biological Chemistry
January 27, 2005

The LIM/homeodomain protein Islet1 recruits Janus tyrosine kinases and signal transducer and activator of transcription 3 and stimulates their activities

Molecular Biology of the Cell
January 19, 2005

A novel sequence in the coiled-coil domain of Stat3 essential for its nuclear translocation

The Journal of Biological Chemistry
May 13, 2003

GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction

March 17, 2003

Protein kinase C  associates with the interleukin-6 receptor subunit gp130 via Stat3 and enhances Stat3-gp130 interaction

Journal of Biological Chemistry

Novel mode of interference with NF-AT regulation in T-cells by the bacterial metabolite n-butyrate

Journal of Biological Chemistry

Glycosphingolipid-induced relocation of Lyn and Syk into detergent resistant membranes results in mast cell activation

Journal of Immunology

The balance between sphingosine and sphingosine-1-phosphate is decisive for mast cell activation after FcRI triggering

The Journal of Experimental Medicine

TNF and IL-5 gene induction in IgE plus antigen stimulated mast cells require common and distinct signaling pathways

International Archives of Allergy and Immunology

Nrf1 in a complex with fos B, c-jun, junD, and ATF2 forms the AP1 component at the TNF promoter in stimulated mast cells.

Nucleic Acid Research

Common and distinct signaling pathways mediate the induction of TNF and IL-5 in IgE plus antigen-stimulated mast cells

The Journal of Immunology

A novel splice variant of the transcription factor Nrf1 interacts with the TNF promoter and stimulates transcription

Nucleic Acid Research

The ultrastructure of the cuticle of Nematoda II. The cephalic cuticle of Stilbonematinae (Adenophoraea, Desmodoridae)



Medizinische Universität Wien

Ph.D.,, Immunology (Prof. Knapp)

Lectures in immunology, FACS analyses, focus on hematology-oncology,
Activities and Societies: Austrian Society of Haematology

Universität Wien

Ph.D., Masters of Science, Cell/ Cellular and Molecular Biology

Wollongong High School



Birgul Gungor Buberci Owner, Egem Ilaç

Birgul Gungor Buberci

Owner, Egem Ilaç



Egem Ilaç
– Present (16 years 4 months)


Hacettepe Üniversitesi



Supplement of API and Dossiers - Product Development -

Consulting of Project and Patent -

Address :
A-11 Blok,A-Kapısı,D:42, 9.Kısım, 34156 ATAKOY-ISTANBUL/ TURKEY

Phone : +90.212559 30 52 - 559 30 72
Fax : +90.212.559 30 19
E-mail : egem@egemilac.com


Pintu Kumar Kundu

Pintu Kumar Kundu.

Pintu Kumar Kundu

Ph.D (Organic Chemistry)
Post Doctoral Fellow
Weizmann Institute of Science, Rehovot · Department of Organic Chem


Dr. Pintu K. Kundu has studied his B.SC. in chemistry from RKMRC, Narendrapur. After doing Master of Science in chemistry from IIT-Madras, he joined Bio-Organic Division, Bhabha Atomic Research Centre (BARC), one of the constituent institutions of HBNI for his Ph.D. in synthetic organic chemistry under the supervision of Prof. Dr. Sunil Kumar Ghosh. Currently he is a postdoctoral fellow at the Department of Organic Chemistry, Weizmann Institute of Science, Israel with Prof. Dr. Rafal Klajn.


Research experience

  • Feb 2012–present
    Synthesis, Properties, and Applications of Photochromic molecules and Functional Porous Materials
    Weizmann Institute of Science · Department of Organic Chemistry · Dr. Rafal Klajn
    Israel · Rehovot
    Post doctoral experience
  • Sep 2006–Jan 2012
    Diversity Oriented Synthetic Strategies for Functionalized Organo-Silicon Compounds and Their Applications
    Bhabha Atomic Research Centre · Bio-Organic Division · Prof. Dr. Sunil K. Ghosh
    India · Mumbai
    Ph.D thesis
  • May 2005–May 2006
    Synthesis of Some Novel N-Glycolipids
    Indian Institute of Technology Madras · Department of Chemistry · Prof. Dr. D. Loganathan
    India · Chennai
    M.Sc. Thesis





  • Feb 2012
    Weizmann Institute of Science
    Organic Chemistry · Post Doctorate
    Israel · Tel Aviv
  • Sep 2006–Jan 2012
    Homi Bhabha National Institute
    Organic Chemistry · Ph.D
    India · Mumbai
  • Jul 2004–Jul 2006
    Indian Institute of Technology Madras
    Chemistry · M.Sc
    India · Chennai
  • Aug 2001–Jul 2004
    Ramakrishna Mission Residential College
    Chemistry (Hons.) · B.Sc
    India · Calcutta

Awards & achievements

  • Feb 2012
    Award: Post Doctoral Fellowship, Weizmann Institute of Science, Israel
  • Jan 2012
    Award: Doctor of Philosophy
  • Sep 2008
    Award: Senior Research Fellowship at BARC, DAE, Govt. of India
  • Jun 2007
    Award: National Eligibility Test (CSIR-NET) qualified
  • Sep 2006
    Award: Junior Research Fellowship at BARC, DAE, Govt. of India
  • Dec 2005
    Scholarship: Merit scholarship holder in M.Sc. IIT Madras
  • Mar 2005
    Award: GATE qualified, Percentile: 98.91, All India Rank: 36
  • Dec 2004
    Scholarship: Merit scholarship holder in M.Sc. IIT Madras
  • Sep 2004
    Award: College award for securing 1st class in B.Sc.
  • Dec 2001
    Scholarship: Merit scholarship holder in B.Sc. RKMRC, Narendrapur
  • Oct 2001
    Award: 1st prize (from school) for securing highest marks in H.S.


  • Languages
    Bengali; Bangla, English, Hindi
  • Scientific Societies
    The Society for Materials Chemistry (SMC)

Erin DiMauro

Dr. Erin DiMauro
  • B.A. in Chemistry
    Wesleyan University
  • Ph.D. in Organic Chemistry (2003)
    University of Pennsylvania
  • Worked in the area of bifunctional catalysis
  • Currently Principal Scientist at Amgen, Boston

Erin DiMauro


  • Department of Medicinal Chemistry
    Thousand Oaks, United States


Principal Scientist, Group Leader

– Present (4 years 3 months)Cambridge, MA
- Medicinal Chemistry team lead and group leader on a variety of projects spanning therapeutic areas (Neuroscience, Oncology, Inflammation) and target classes (Ion channels, kinases, GPCRs, PARPs, proteases, transporters).
- Extensive experience in lead generation and optimization: delivery of high quality tools for target validation and milestone leads for project advancement.
- Direct management of organizational units comprised of B.S., M.S., and Ph.D. Interns, Associates, Scientists, and Senior Scientists.
- Routine internal and external presentations. Consistent publication in leading journals.

Senior Scientist, Group Leader

(6 years 1 month)Cambridge, MA


(2 years 6 months)Cambridge, MA



GlyRa3 (Neuroscience)

Nav1.7 (Neuroscience)

Tankyrase (Oncology)

Ck1g (Oncology)

BACE (Neuroscience)

CB2 (Neuroscience)

Lck (Inflammation)

Erin F Dimauro




Uday Neelam

Dr. Uday Neelam
  • B.Sc. in Chemistry
    Kakatiya University, India
  • M.Sc. in Chemistry
    National Institute of Technology at Warangal, India
  • Ph.D. in Chemistry
    Osmania University, India
  • Scientist at Dr.Reddy's Laboratories, India
  • Visiting Scholar 2014-2015

mobile no 9704044420
Uday Kumar Neelam (@udaykumarneelam) | Twitter


Our research work is mainly focused on development of an efficient (IP free), Plant friendly, cost-effective, and commercially viable synthetic method for a given drug molecule. Our development work reaches end by attaining desired polymorph with ICH quality of final API, thorough understanding on impurity profile of whole synthesis, and implementation on manufacturing scale.


Assistant Manager/Scientist

Dr. Reddy's Laboratories
– Present (4 years 4 months)Hyderabad Area, India
Development of novel and environmentally friendly processes for pharmaceutical agents

Visiting Scholar

University of Pennsylvania
(1 year)Roy and Diana Vegelos Laboratories for Advanced Science and Technology
Worked on C-C bond formation via C-H activation using Pd(II).
Advisor: Dr. Marisa C. Kozlowski, Professor of Chemistry, Philadelphia, USA

Junior Manager

Dr Reddy’s Laboratories Ltd
(2 years 1 month)

Senior Executive – R&D

Dr Reddy’s Laboratories Ltd
(3 years 1 month)

Trainee Chemist – R&D

Dr. Reddy's Laboratories
(1 year 3 months)

Honors & Awards

1. IPDO award for significant contribution in achieving API cost leadership in Prazole drug synthesis by developing common platform technology from IPDO-Head and CEO, Dr. Reddy’s (2007)

2. Best Poster award in Technical conclave” conducted on Chemistry and Process Engineering (2009)

3. PSAI excellence award – Excellence in Project Execution” of new antiulcerative drug – Enantiopure sulphoxide derivative from PSAI-Head, Dr. Reddy’s. (2009)

4. IPDO Utasv 2009” – High performance team award from SBU-Head, Dr. Reddy’s. (2009)


1. Process for the Preparation of Cinacalcet

United States PCT 058235 A2, 2008.

2. Methods for Preparing Cinacalcet Hydrochloride

United States PCT 058236 A2, 2008.

3. A Process for the Preparation of Benzimidazole Derivatives and their salt

United States PCT 045777 A2, 2008.

4. Dexlansoprazole Process and Polymorphs

United States PCT 117489 A1, 2009

5. Decitabine Process and Crystalline Form

United States PCT 129211 A2

6. Aliskiren Hemifumarate Process and their Intermediates

United States PCT 021446

7. Dexlansoprazole with Pharmaceutical excipients

United States US WO 0263475 A1

8. Synthesis and Characterization of potential impurities of Aliskiren and its intermediates

United States 2011/CHE/2012


1. An Improved Process for the Production of Lansoprazole: Investigation of Key Parameters That Influence the Water Content in Final API

Org. Process Res. Dev., 2010, 14 (1), 229–233

2. An efficient synthesis of dexlansoprazole employing asymmetric oxidation strategy

Tetrahedron Letters., 2011, 52( 42), 5464-5466

3. (R)-(+)-2-{[(3-Methyl-4-nitro-pyridin-2-yl)meth-yl]sulfin-yl}-1H-benzimidazole.

Acta Crys., 2011, E67, o2190

4. Iron triflate mediated reductive amination of aldehydes using sodium borohydride

Tetrahedron Letters., 2012, 53, 4354-4358

5. Metathesis approach to the formal synthesis of aliskiren.

Chemistry & Biology Interface., 2013, 3, 1, 14-17

6. Regioselective methylation of indazoles using methyl 2,2,2-trichloromethyl-acetimidate.

Tetrahedron Letters., 2013, 54 1661

7. Zinc Triflate Catalyzed Acetylation of Alcohols, Phenols and Thiophenols.

Tetrahedron Letters., 2013

8. Identification, characterization and synthesis of potential impurities of Aliskiren Hemifumarate, an antihypertensive drug

Chemistry & Biology Interface., 2013, 3, 5, 304-313.

9. Synthesis of Bis(indolyl)methanes by using ferric triflate as catalyst

Chemistry & Biology Interface., 2013, 3, 5, 334-338

10. Scalable synthesis of 3-amino-2, 2-dimethylpropanamide: A key intermediate for Aliskiren

Chemistry & Biology Interface., 2014, 4, 1, 36-43

11. Zinc triflate catalyzed synthesis of thioethers.

Chemistry & Biology Interface, 2014, 4, 131-136.

12. Alternative Route towards the Convergent Synthesis of an Orally Active Renin Inhibitor Aliskiren.

Chemistry & Biology Interface, 2014, 4, 363-373.

13. Ferric Triflate Fe(OTf)3 as a Highly Efficient Catalyst for the Acetylation of Alcohols, Phenols, Thiols and Amines: Reaction Mechanism Understanding through Density Functional Theory.

Chemistry & Biology Interface, 2014, 4, 263-267.

14. Comproportionation based Cu(I) catalyzed [3+2] cycloaddition of nitriles and sodium azide

Chemistry & Biology Interface, 2015, 5, 51-62.

15. Investigation of a Kumada Cross Coupling Reaction for Large-Scale Production of (2S, 7R, E)-2-Isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-N,N,8-trimethylnon-4-enamide

Org. Process Res. Dev., 2015, 19, 3, 470–475


Osamina University

Ph.D, Chemistry

Thesis Title: “synthesis of few pharmaceutically active compounds and their related substances”

Kakatiya University

B. Sc, Biotechnology